Replies to post #147073 on Biotech Values

[mcbio]

I've posted here before on issues with previous P38 programs

It's unclear to me if the "graveyard" reference in your link includes p38 inhibitors that have been tested against pain and, specifically, patients who are no longer responsive to NSAIDs and cannot tolerate opioids. This is the patient population that ARRY is targeting with 797 and it's a very large market and unmet need according to ARRY.

[turtlepower]

Thanks for the link. I missed that post.

Intriguing information about the CRP level returning to baseline after a few weeks. The CRP level is tied to inflammation if I understand correctly so that probably means that with 797 a longer treatment period is warranted to ensure the treatment effect stays. Is that read correct?